CompletedNot Applicable

Impact of Underlying Renal Disease and Immunosuppressive Regimen on Ovarian Reserve in Renal Patients

Poland153 participantsStarted 2018-06-01

Plain-language summary

Aging, renal pathology (eg SLE, ADPKD), X-ray exposition and pharmacological treatments, especially previous strong immunosuppression, may negatively influence the ovarian reserve in childbearing age women. Anti-Müllerian hormone (AMH) is regarded as biomarker for ovarian reserve. Every female with renal disease regularly menstruating that met exclusion criteria could have participated. The aim was to assess ovarian reserve in female patients with normal menstrual cycle and kidney disease, including kidney transplant recipients.

Who can participate

Age range18 Years – 44 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Conscious written approval * Autoimmunological disorder with kidneys affection/ kidney transplant recipient- Regular menstrual cycles * Age above 18 years old Exclusion Criteria: * Irregular menstrual cycles * Menopause * PCOS * Chemiotherapy or radiotherapy in the past * Surgical interventions within ovaries * Hypogonadotropic hypogonadism * Folliculoma * Age under 18 years old

What they're measuring

To compare AMH levels between three groups

Timeframe: 1 day

Potential impact of X-ray exposition on ovarian reserve

Timeframe: 1 day

Potential impact of antiproliferative drugs on ovarian reserve

Timeframe: 1 day

Potential impact of underlying kidney disease on ovarian reserve

Timeframe: 1 day

Trial details

NCT IDNCT04762615

SponsorWroclaw Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-11-10

View on ClinicalTrials.gov More Anti-Mullerian Hormone Deficiency trials